Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. That is the direct, unambiguous answer — and it comes from the medicine's licensed prescribing information, not caution for caution's sake. If you are pregnant or planning a pregnancy, this is the most important clinical fact about tirzepatide you will read. The rest of this page explains what sits behind that guidance, what happens if you discover a pregnancy while on treatment, and how to talk to the right people about your options. These are prescription-only medicines; every decision about starting, stopping or switching must involve a prescriber or GP who knows your full picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks is whether Mounjaro can simply be paused during early pregnancy and restarted afterwards. The thinking is understandable (many medicines are paused rather than stopped entirely) but it misreads the guidance here. Tirzepatide is not paused in pregnancy; it is not used in pregnancy. The reasoning goes beyond a precautionary label. Animal reproductive toxicology studies identified adverse developmental effects at exposure levels that are clinically relevant. Because there are no robust human pregnancy data, the risk to a developing foetus cannot be quantified or dismissed.
The NHS medicines page for tirzepatide is explicit: Mounjaro should not be used if you are pregnant or breastfeeding. It is also not suitable for people trying to get pregnant. That is the clinical line, not a hedge. If you are on treatment and pregnancy becomes a possibility (or a discovery) the conversation belongs with your prescriber or GP, not a self-managed pause. You can explore the broader picture of Mounjaro and pregnancy in more detail, but the starting point is always the same: stop, seek clinical advice, and do not restart without that conversation.
Discovering a pregnancy mid-treatment is not a reason to panic, but it is a reason to act the same day. Contact your prescriber or GP and let them know. They will advise on stopping the medicine and will want to ensure appropriate antenatal care is in place. Tirzepatide has a half-life that means it clears the body over time, but clinicians manage this on a case-by-case basis rather than following a fixed patient-led rule.
The MHRA recommends that women of childbearing potential use effective contraception while on GLP-1 receptor agonist medicines, and for a defined period afterwards before attempting conception. For tirzepatide specifically, there is an additional consideration: the medicine slows gastric emptying, which can reduce the absorption of oral contraceptives, particularly in the first weeks of treatment and after each dose increase. NHS England's guidance on weight-management injections advises that women using the oral contraceptive pill should add a non-oral method (such as condoms) for the first four weeks of treatment and for four weeks after every dose step up. That recommendation exists precisely to prevent an unplanned pregnancy in this setting. You can read more about the specifics of how Mounjaro may affect pregnancy and the underlying mechanisms involved.
If you have questions about tirzepatide and conception timing specifically, our clinical team profiles, including our lead prescriber, give a sense of who reviews these cases.
For people who have completed a course of treatment and want to conceive, the key question is timing. Official guidance recommends a wash-out period before trying to conceive, though the exact duration is a clinical judgement rather than a universal fixed number of weeks. The half-life of tirzepatide, the dose you were taking, and your individual circumstances all feed into that discussion. This is territory for your GP or a specialist, not a generalised online answer.
What is better understood is that achieving and sustaining a healthier weight before pregnancy carries its own benefits for fertility and pregnancy outcomes. Obesity is associated with increased risks during pregnancy, and weight loss achieved before conception (through any evidence-based route) may improve those risks. The question of Mounjaro after pregnancy is a separate clinical consideration, particularly for those who are breastfeeding, since the medicine is not recommended during lactation either.
Polycystic ovary syndrome (PCOS) is another area worth acknowledging here. PCOS is a common cause of fertility difficulties and is often associated with insulin resistance. Some people ask specifically about Mounjaro, PCOS and pregnancy, whether the medicine's effect on metabolic factors might influence fertility. That is an active area of clinical interest, but one where individual specialist input is essential; it is not a straightforward yes or no.
If your situation involves pregnancy, conception or breastfeeding, your GP or an obstetrician with access to your full medical history is the right first point of contact. A prescribing pharmacist at an online pharmacy (including ours) can review eligibility for treatment when you are not pregnant and not trying to conceive, but managing the intersection of GLP-1 therapy and reproductive planning is a broader clinical conversation.
For people who are not pregnant, not breastfeeding and not currently trying to conceive, and who are exploring weight management options, starting a free consultation with our prescribers is the right next step. Every consultation at nume is reviewed personally by a GPhC-registered Independent Prescriber, and that includes a careful assessment of your circumstances. Questions about alcohol and treatment interactions, covered separately on our Mounjaro and alcohol page, follow the same clinician-first approach.
If you are weighing up your broader options before deciding anything, the weight loss treatment overview is a good place to start, and our Mounjaro pillar page covers the medicine in full. Cost questions have their own dedicated space on the Mounjaro cost page. And if you have a question that none of these pages answer, our team is available seven days a week.
One final note from the tirzepatide and pregnancy guidance angle: the available evidence, the licensed prescribing information, and NHS guidance all point the same direction. Pregnancy is not a grey area for this medicine. That clarity, while it may feel limiting, is actually useful, it means the right path is unambiguous, even if the individual steps require a clinical conversation to navigate properly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.